CONTINUING BESIFOVIR DIPIVOXIL MALEATE VERSUS SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE FOR TREATMENT OF CHRONIC HEPATITIS B: RESULTS OF 192-WEEK PHASE 3 TRIAL

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial

Background/Aims Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus.Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir disoproxil fumarate (TDF) and better safety profiles in terms of improved renal and bone safety.This extension stu

read more